Journal News

JBC: Blocking potato blight’s
ability to set up shop

John Arnst
Nov. 1, 2016

True to its name, Phytophthora infestans is a destroyer of plants. (In Greek, “phyto” means “plant”; “phthora” means “ruin.”) Most notorious for the Irish potato famine, the pathogen also can target other members of the Solanaceae family of plants, which includes tomatoes, spices, weeds, herbs and vines. While a global, potato-based famine isn’t imminent, the pathogen still causes about $6 billion of damage to crops of the versatile tubers each year, according to the American Phytopathological Society.

In a Paper of the Week recently published in the Journal of Biological Chemistry, researchers in the U.K. report detailed crystallographic information about the interaction between one of the pathogen’s effector proteins and one of the potato’s proteins. They ultimately hope to exploit this result to engineer plants that are resistant to the pathogen.

JBC-blocking-blight-primary.jpg
A potato showing the characteristic signs of blight.
AGRICULTURAL RESEARCH SERVICE


“If you can understand interactions and then modify the host–cell target in such a way that it retains its original function in the plant, but is no longer able to be acted on by the effector, that might push the balance of the disease progression in the favor of the plant,” says Mark Banfield at the John Innes Centre, the senior author on the paper.

According to Banfield, the effectors, which tend to be small proteins that bind to specific host proteins and modify their activity, often possess dual activities for host and pathogen. “One of them is to work on behalf of the pathogen to manipulate host cells for their own benefit,” he says. “But the plants have also evolved ways of recognizing the presence of these molecules as foreign objects inside cells and then are able to mount a response to those molecules directly.”

Banfield and his colleagues at the Sainsbury Laboratory Norwich and the Imperial College London, with whom he collaborated on the current paper, previously had characterized the PexRD54 effector protein of Phytophthora infestans and verified its interaction with the host cells’ ATG8 proteins. Their characterization appeared in the journal eLife earlier this year.

ATG8 is a protein located in the membranes of eukaryotes’ autophagosomes, which are double-layered membrane organelles involved in delivering damaged cellular structures to the lysosomes for degradation, among other functions. PexRD54 works on behalf of the pathogen by binding to this protein in host cells and interfering with its ability to perform its normal cellular function.

For this JBC paper, the investigators wanted to explore further the interaction. The researchers first determined the crystal structure of PexRD54. They then focused on the protein’s disordered C-terminus, a region of around 10 to12 amino acids that the researchers knew bound directly to the ATG8 molecule, and used X-ray crystallography to show the complex.

With the components of the linked region well defined, they then turned to a low-resolution technique known as small-angle X-ray scattering to get an image of the surface of the entire bound protein complex. They were then able to dock the separately defined features, including the individual proteins and the interacting region, into the protein surface, forming a complete image of the interaction.

With this interaction now well characterized, Banfield and his colleagues hope to engineer the ATG8 protein to ignore the presence of the PexRD54 effector from the pathogen.

“If we can engineer that molecule in the plant cell to no longer be perturbed by the presence of the effector, clearly the pathogen has then lost the benefit of delivering that effector to host cells,” Banfield said. “It goes all the way to delivering it, but it no longer has the activity that it’s evolved to have.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
John Arnst

John Arnst was a science writer for ASBMB Today.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Spider-like proteins spin defenses to control immunity
News

Spider-like proteins spin defenses to control immunity

Oct. 17, 2025

Researchers from Utrecht University discovered two distinct binding modes of a spider-shaped immune inhibitor found in serum.

A biological camera: How AI is transforming retinal imaging
Feature

A biological camera: How AI is transforming retinal imaging

Oct. 15, 2025

AI is helping clinicians see a more detailed view into the eye, allowing them to detect diabetic retinopathy earlier and expand access through tele-ophthalmology. These advances could help millions see a clearer future.

AI in the lab: The power of smarter questions
Essay

AI in the lab: The power of smarter questions

Oct. 14, 2025

An assistant professor discusses AI's evolution from a buzzword to a trusted research partner. It helps streamline reviews, troubleshoot code, save time and spark ideas, but its success relies on combining AI with expertise and critical thinking.

Training AI to uncover novel antimicrobials
Feature

Training AI to uncover novel antimicrobials

Oct. 9, 2025

Antibiotic resistance kills millions, but César de la Fuente’s lab is fighting back. By pairing AI with human insight, researchers are uncovering hidden antimicrobial peptides across the tree of life with a 93% success rate against deadly pathogens.

AI-designed biomarker improves malaria diagnostics
Journal News

AI-designed biomarker improves malaria diagnostics

Oct. 8, 2025

Researchers from the University of Melbourne engineered Plasmodium vivax diagnostic protein with enhanced yield and stability while preserving antibody-binding, paving the way for more reliable malaria testing.

Matrix metalloproteinase inhibitor reduces cancer invasion
Journal News

Matrix metalloproteinase inhibitor reduces cancer invasion

Oct. 8, 2025

Scientists at the Mayo Clinic engineered a TIMP-1 protein variant that selectively inhibits MMP-9 and reduces invasion of triple-negative breast cancer cells, offering a promising tool for targeted cancer research.